Kynam Capital Management, LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Kynam Capital Management, LP reported 36 stock positions worth $1.6 billion. Its top holding was Syndax Pharmaceuticals (SNDX) at 11.9% of the portfolio, followed by Celldex Therapeutics (CLDX, 11.8%) and Vaxcyte (PCVX, 10.8%). Compared with Q4 2025, it opened 4 new positions, sold out of 3, added to 12 and reduced 9. The biggest buy was a new position in Urogen Pharma (URGN) and the biggest sale Cogent Biosciences (COGT, shares −35%).
- Most Recent 13F
- Q2 2026
- Location
- PRINCETON, NJ
- CIK
- 0001907884
- Portfolio Value
- $1.6B (Q1 2026)
- SEC Filing
- 0001907884-26-000007 ↗ filed May 15, 2026
Holdings Value
Holdings 36 stocks · $1.6B
| SNDX Syndax Pharmaceuticals Inc. | 11.94% | 8,050,959 | $188.1M | No change |
| CLDX Celldex Therapeutics Inc. | 11.76% | 5,840,567 | $185.3M | Reduce -1.7% |
| PCVX Vaxcyte Inc. | 10.78% | 2,922,335 | $169.8M | No change |
| COGT Cogent Biosciences Inc. | 9.86% | 4,037,331 | $155.4M | Reduce -34.5% |
| VERA Vera Therapeutics Inc. | 8.68% | 3,398,224 | $136.7M | Reduce -1.0% |
| BEAM Beam Therapeutics Inc. | 5.57% | 3,682,185 | $87.7M | Add +50.9% |
| CTMX Cytomx Therapeutics Inc. | 4.48% | 15,013,093 | $70.6M | Add +67.4% |
| BCRX Biocryst Pharmaceuticals Inc. | 3.43% | 5,680,795 | $54.1M | Reduce -39.4% |
| TVTX Travere Therapeutics Inc. | 2.96% | 1,569,018 | $46.6M | Add +203.0% |
| VRDN Viridian Therapeutics Inc. | 2.91% | 2,341,652 | $45.8M | Add +59.2% |
| CGEM Cullinan Therapeutics Inc. | 2.81% | 3,114,132 | $44.3M | No change |
| URGN Urogen Pharma Ltd. | 2.56% | 2,247,393 | $40.4M | New |
| KALV Kalvista Pharmaceuticals Inc. | 2.33% | 1,820,954 | $36.7M | Add +0.6% |
| APLS Apellis Pharmaceuticals Inc. | 2.11% | 825,000 | $33.2M | Reduce -9.2% |
| LEGN Legend Biotech Corp.-ADR | 1.81% | 1,576,295 | $28.5M | New |
| MBX MBX Biosciences Inc. | 1.77% | 934,799 | $27.9M | No change |
| IMCR Immunocore Holdings PLC-ADR | 1.69% | 884,937 | $26.7M | Add +3.3% |
| STRO Sutro Biopharma Inc. | 1.38% | 872,558 | $21.7M | Add +81.9% |
| BNR Burning Rock Biotech Ltd.-ADR | 1.26% | 1,227,555 | $19.8M | Add +23.4% |
| SLNO Soleno Therapeutics Inc. | 1.19% | 560,000 | $18.7M | New |
| NRIX Nurix Therapeutics Inc. | 1.18% | 1,194,757 | $18.5M | Reduce -39.4% |
| PHVS Pharvaris NV | 1.15% | 640,395 | $18.1M | No change |
| EVMN Evommune Inc. | 0.91% | 625,496 | $14.4M | Add +237.2% |
| RLAY Relay Therapeutics Inc. | 0.90% | 1,424,259 | $14.2M | No change |
| GERN Geron Corp. | 0.65% | 6,836,318 | $10.2M | Add +97.8% |
| ENGN Engene Holdings Inc. | 0.59% | 1,356,843 | $9.2M | Reduce -9.1% |
| DSGN Design Therapeutics Inc. | 0.53% | 784,606 | $8.3M | No change |
| WVE Wave Life Sciences Ltd. | 0.44% | 965,193 | $7.0M | Reduce -55.5% |
| CLYM Climb Bio Inc. | 0.44% | 1,003,341 | $6.9M | Reduce -2.4% |
| AMRN Amarin Corp. PLC -ADR | 0.43% | 472,382 | $6.8M | Add +21.4% |
| BHVN Biohaven Ltd. | 0.38% | 702,884 | $5.9M | No change |
| PRLD Prelude Therapeutics Inc. | 0.35% | 1,592,551 | $5.4M | Add +101.9% |
| CRBU Caribou Biosciences Inc. | 0.30% | 2,503,302 | $4.8M | No change |
| ALEC Alector Inc. | 0.27% | 2,000,000 | $4.3M | No change |
| PRQR Proqr Therapeutics NV | 0.16% | 1,566,317 | $2.5M | No change |
| CADL Candel Therapeutics Inc. | 0.06% | 200,000 | $980K | New |
Options reported separately and not counted above: TVTX calls ($23.8M), RVMD puts ($20.2M), TVTX puts ($1.6M).
Portfolio Sells Q4 2025 → Q1 2026
| COGT Cogent Biosciences Inc. | Reduce -34.5% | 9.86% | −4.39 |
| TYRA Tyra Biosciences Inc. | Sold out | 0.00% | −2.68 |
| VERA Vera Therapeutics Inc. | Reduce -1.0% | 8.68% | −2.64 |
| CGON CG Oncology Inc. | Sold out | 0.00% | −2.56 |
| WVE Wave Life Sciences Ltd. | Reduce -55.5% | 0.44% | −1.96 |
| DVAX Dynavax Technologies Corp. | Sold out | 0.00% | −1.38 |
| BCRX Biocryst Pharmaceuticals Inc. | Reduce -39.4% | 3.43% | −1.32 |
| NRIX Nurix Therapeutics Inc. | Reduce -39.4% | 1.18% | −1.26 |
| ENGN Engene Holdings Inc. | Reduce -9.1% | 0.59% | −0.29 |
| CLYM Climb Bio Inc. | Reduce -2.4% | 0.44% | +0.17 |
| APLS Apellis Pharmaceuticals Inc. | Reduce -9.2% | 2.11% | +0.62 |
| CLDX Celldex Therapeutics Inc. | Reduce -1.7% | 11.76% | +1.25 |
Portfolio Buys Q4 2025 → Q1 2026
| URGN Urogen Pharma Ltd. | New | 2.56% | +2.56 |
| CTMX Cytomx Therapeutics Inc. | Add +67.4% | 4.48% | +1.99 |
| LEGN Legend Biotech Corp.-ADR | New | 1.81% | +1.81 |
| TVTX Travere Therapeutics Inc. | Add +203.0% | 2.96% | +1.67 |
| SLNO Soleno Therapeutics Inc. | New | 1.19% | +1.19 |
| BEAM Beam Therapeutics Inc. | Add +50.9% | 5.57% | +1.17 |
| STRO Sutro Biopharma Inc. | Add +81.9% | 1.38% | +1.02 |
| EVMN Evommune Inc. | Add +237.2% | 0.91% | +0.71 |
| KALV Kalvista Pharmaceuticals Inc. | Add +0.6% | 2.33% | +0.42 |
| GERN Geron Corp. | Add +97.8% | 0.65% | +0.35 |
| PRLD Prelude Therapeutics Inc. | Add +101.9% | 0.35% | +0.20 |
| AMRN Amarin Corp. PLC -ADR | Add +21.4% | 0.43% | +0.08 |
| CADL Candel Therapeutics Inc. | New | 0.06% | +0.06 |
| BNR Burning Rock Biotech Ltd.-ADR | Add +23.4% | 1.26% | −0.05 |
| VRDN Viridian Therapeutics Inc. | Add +59.2% | 2.91% | −0.07 |
| IMCR Immunocore Holdings PLC-ADR | Add +3.3% | 1.69% | −0.24 |
Options Activity Q4 2025 → Q1 2026
| BEAM Beam Therapeutics Inc. | call | Sold out | 937,000 | $26.0Mbefore exit |
| TVTX Travere Therapeutics Inc. | call | New | 800,000 | $23.8M |
| RVMD Revolution Medicines Inc. | put | New | 207,500 | $20.2M |
| OMER Omeros Corp. | put | Sold out | 200,000 | $3.4Mbefore exit |
| TVTX Travere Therapeutics Inc. | put | New | 54,900 | $1.6M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 32 | $1.8B | CLDX, SNDX, PCVX, COGT, VERA |
| Q1 2026 | 36 | $1.6B | SNDX, CLDX, PCVX, COGT, VERA |
| Q4 2025 | 35 | $1.5B | COGT, VERA, SNDX, CLDX, PCVX |
| Q3 2025 | 35 | $1.3B | CLDX, SNDX, VERA, COGT, PCVX |
| Q2 2025 | 31 | $928.8M | CLDX, PCVX, VERA, SNDX, BCRX |
| Q1 2025 | 31 | $1.2B | NTRA, PCVX, CLDX, SNDX, BCRX |
| Q4 2024 | 29 | $1.5B | NTRA, PCVX, CLDX, SNDX, DVAX |
| Q3 2024 | 24 | $1.3B | NTRA, PCVX, CLDX, SNDX, COGT |
| Q2 2024 | 22 | $955.2M | NTRA, CLDX, SNDX, DVAX, COGT |
| Q1 2024 | 21 | $898.9M | NTRA, SNDX, CLDX, VERA, COGT |